Baxter Healthcare to Sell New Blood-Clotting Drug

Baxter Healthcare Corp.’s Glendale-based Hyland division said it will begin U.S. distribution of a drug made by Kabi Vitrum AB, a Swedish pharmaceutical company, for patients with antithrombin III deficiency, a hereditary disorder that impairs proper blood clotting.

The drug, ATnativ, received approval from the U.S. Food and Drug Administration last December for marketing as an orphan drug, the term used for treatments for diseases with a patient population of 200,000 or less. ATnativ has been available in several European countries for clinical trials since the mid-1970s.

Baxter Healthcare is a unit of Baxter International, a major health-care products and services concern based in Deerfield, Ill.